The purpose of this study was to determine the extent to which 24-2 metrics, commonly used in clinical practice, miss macular damage and, to evaluate the patterns of damage most frequently missed by these metrics. The most sensitive 24-2 VF metric, CC, missed 7 (12%) of the eyes with confirmed macular damage, and the least sensitive 24-2 VF metric, MD, missed 20 (34%). Thus, these common metrics miss macular damage documented on both OCT macular scans and 10-2 VFs. The patterns of damage missed included shallow and deep local damage, as well as widespread damage. Interestingly, the CC metric, designed to detect local damage, was the most sensitive for detecting widespread macular damage.
To compensate for the inability of the MD, PSD, GHT, and CC 24-2 metrics to detect macular damage, some clinicians examine the TD values of a few central points. We attempted to mimic this strategy with our MPs metric. However, this metric still missed 9 (15%) of the 59 abnormal macula eyes.
Additionally, many clinicians judge glaucomatous damage based upon the PD plot rather than the TD plot. In particular, when the 24-2 TD plot shows generalized depressed sensitivity and the PD plot is normal, they conclude that there is no significant damage to the macula and surrounding area. However, these eyes can sometimes have widespread macular damage.
10 This is evident in
Figures 3B and
3C, where the cpRNFL thickness plot and combined 10-2 and OCT macular probability plots show macular damage that is not evident on the 24-2 PD plots.
While previous work argued that tests with a 6° grid missed damage detected by the 10-2 grid,
5,9 it was not possible to get accurate measures of sensitivity as there was no “gold standard” for macular damage. To minimize this problem, we created a reference standard based upon both 10-2 VF and OCT tests. In particular, the macular was considered abnormal only if the 10-2 TD and the RGC+ and/or RNFL probability plot showed abnormal regions that topographically agreed. While theoretically our approach can result in an eye falsely classified as abnormal, false-positives should be rare given that the VF and OCT results should have largely independent sources of error and our criteria of an abnormal 10-2 were relatively conservative (see Methods).
Even with this relatively strict definition of an abnormal macula, the individual 24-2 metrics missed 12% or more of these eyes. In order to improve the sensitivity of the 24-2, it is possible to combine the information provided by the various metrics as clinicians frequently do in practice, but this will only increase the number of eyes falsely identified as having macular damage. In any case, combining the most common metrics (GHT and PSD) did not improve sensitivity compared to PSD alone. To put this in perspective, this common set of criteria missed 10 (17%) of the eyes classified as abnormal macula.
Given the prevalence of early macular damage, patients should not be screened with only the 24-2 VF. Although our 141 patients were a mix of suspects and patients with mild glaucoma (i.e., MD better than −6.0 dB), over 40% of them had macular damage as defined by our 10-2 and OCT analysis. This estimate is conservative as it does not include the eyes with macular damage that were classified as abnormal on only the 10-2 VF or the OCT macular scans.
What are the alternatives? We are not suggesting replacing the 24-2 VF with a 10-2 VF. In a population of patients similar to ours, Traynis et al.
9 found that the percentage of eyes classified as normal on the 10-2 VF, but abnormal on the 24-2 VF, was approximately the same as the percentage normal on the 24-2 VF, but abnormal on the 10-2 VF. We believe the preferred solution is to use a modified 24-2 pattern.
19,20 For example, adding 16 of the points from the 10-2 pattern to the 24-2 pattern will identify most of the eyes with macular damage with the same number of test points in the 10-2 pattern.
20 However, we realize this will not be feasible until manufacturers make it easy to compare the results of this modified 24-2 to previous 24-2 tests, as well as to normative values. Until an improved 24-2 VF is available commercially, we favor the current practice followed by some clinicians of alternating 24-2 and 10-2 VFs on successive visits, although this does have the disadvantage of decreasing the number of tests available for progression analysis. In any case, 10-2 VF results should be combined with OCT macular RGC+ probability plots.
15